Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Down 26.5% in December

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 29,780 shares, a decline of 26.5% from the December 15th total of 40,499 shares. Approximately 4.1% of the shares of the stock are short sold. Based on an average daily volume of 45,777 shares, the short-interest ratio is presently 0.7 days. Based on an average daily volume of 45,777 shares, the short-interest ratio is presently 0.7 days. Approximately 4.1% of the shares of the stock are short sold.

Quoin Pharmaceuticals Trading Down 3.7%

Shares of QNRX opened at $10.27 on Friday. The firm has a market cap of $8.63 million, a P/E ratio of -0.32 and a beta of 1.59. Quoin Pharmaceuticals has a 12-month low of $5.01 and a 12-month high of $41.80. The company’s 50-day moving average price is $14.59 and its 200 day moving average price is $10.91.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its earnings results on Thursday, November 6th. The company reported ($6.71) earnings per share for the quarter, missing the consensus estimate of ($6.36) by ($0.35). Equities research analysts forecast that Quoin Pharmaceuticals will post -2.05 earnings per share for the current year.

Institutional Investors Weigh In On Quoin Pharmaceuticals

A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Aberdeen Group plc purchased a new stake in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 75,000 shares of the company’s stock, valued at approximately $1,082,000. Aberdeen Group plc owned approximately 8.93% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 8.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, December 22nd. Wall Street Zen upgraded Quoin Pharmaceuticals to a “sell” rating in a report on Saturday, November 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.